 |
|
|
| |
DTG vs LPV/r (DAWNING): Efficacy by
Baseline NRTI Resistance and Second-Line NRTI Use
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
Dannae Brown,1 Ruolan Wang,2 Mark Underwood,2 Judy Hopking,3 Maria Claudia Nascimento,4 Michael Aboud,4 Jorg Sievers4
1Viiv Healthcare, Abbotsford, Australia; 2ViiV Healthcare, Research Triangle Park, NC; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Brentford, UK
WEBCAST: http://www.croiwebcasts.org/console/player/41313?mediaType=slideVideo&
|
| |
|
|
|
|
|
